Press release
Please enter a searchword.

27/08/08
First half year 2008 : a 19% increase in operating profit and net profit
Category: Group activities

The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financial statement :

24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses

Stallergenes has been granted with the market authorization in Germany for its sublingual desensitisation tablet Oralair® Grasses.

28/07/08
Phase III clinical trial for Staloral® 300 in China
Category: R&D

Stallergenes launches a phase III clinical trial for Staloral® 300 in China

10/06/08
Phase II/III clinical trial on a tablet for desensitisation to mites
Category: R&D

Stallergenes has started a phase II/III clinical trial on a tablet for desensitisation to mites

21/03/08
A new logo for Stallergenes
Category: Group activities

In order to pursue its development and to reach its future objectives, Stallergenes is adopting a new logo.

 

12/03/08
2007 Results
Category: Group activities, Finance

Further profit growth; Sales up 16%;

Profit before R&D up 19%;

 

Net profit (group share) up 12%;

Acceleration of R&D expenditure

 

 

15/01/08
Quarterly information

2007: A further year of strong growth: up 16%

13/12/07
Partnership for producing mites recombinant allergens
Category: R&D

Partnership agreement between STALLERGENES and PROTEIN’EXPERT

28/11/07
Oralair® Grasses: Positive results of VO52.06 paediatric study
Category: Group activities, Finance

The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.

 

 

28/08/07
2007 half-year results

Strong business growth +17%

Earnings per share up 30%

 

14/05/07
Stallergenes and CMC BIOPHARMACEUTICALS sign manufacturing agreement

Signature of an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk.

 

15/03/07
Increase in operating profit and additional R&D efforts
Category: Finance

2006: Another year of growth